Oric Pharmaceuticals Q3 2026: Loss Widens as Phase 3 Spending Surges

As seen on the 24/7 Wall St. homepage on November 16, 2026.

ORIC Oric Pharmaceuticals
Q3 2026
EPS
-$0.44
est -$0.38 -15.2%
Revenue
$0K

The wider loss is the cost of going late-stage: R&D jumped to $43.4 million from $28.8 million as Oric launched the Himalayas-1 Phase 3 trial of rinzimetostat with Bayer's darolutamide in prostate cancer. Management says $345.4 million in cash carries operations into the second half of 2028, past that trial's primary endpoint readout.

Continue ReadingShow less

Oric Pharmaceuticals reported a GAAP loss of $0.44 per share for Q3 2026, missing expectations. The company generates no product revenue, so the entire story this quarter is about how fast it is spending and what that spending is buying.

The main driver of the wider loss was a sharp jump in research and development expenses, which rose to $43.4 million. The increase was tied primarily to external costs for rinzimetostat as Oric formally launched Himalayas-1, a global Phase 3 registrational trial testing the PRC2 inhibitor alongside Bayer's darolutamide in metastatic castration-resistant prostate cancer.

Oric's second pipeline asset, enozertinib, added an encouraging data point at ESMO 2026, posting an 84% confirmed systemic response rate in first-line EGFR atypical non-small cell lung cancer. A Phase 3 trial for that program, called Redwood-1, is planned to start in the first half of 2027, putting two late-stage programs in motion within the next few quarters.

Sponsored

The balance sheet provides the clearest signal of how long the company can sustain this spending pace. Management said $345.4 million in cash, cash equivalents, and investments funds operations into the second half of 2028, a runway that extends past the anticipated primary endpoint readout from Himalayas-1. That readout is what investors are ultimately underwriting with every dollar of losses posted today.

Looking at the recent earnings history, the Q3 2026 miss breaks a streak of several quarters where Oric had come in at or better than Wall Street's loss estimates. The reversal reflects the deliberate step-up in trial costs rather than any operational deterioration, but investors will be watching whether R&D spend continues to climb as both Phase 3 programs gain momentum.

Mentioned: ORIC